Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

Keyphrases

• Drug Survival 100%
• Moderate-to-severe Psoriasis 100%
• Ixekizumab 100%
• Secukinumab 100%
• Denmark 10%
• Follow-up Time 10%
• National Cohort Study 10%
• Number of Patients 10%
• Naïve Patients 10%
• Survival Curve 10%
• Previous Treatment 10%
• Psoriasis 10%
• Interleukin-17 (IL-17) 10%
• Kaplan-Meier Plot 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriasis Vulgaris 100%
• Secukinumab 100%
• Ixekizumab 100%
• Biological Product 30%
• Psoriasis 20%
• Survival Rate 10%
• Interleukin 17 10%

Immunology and Microbiology

• Ixekizumab 100%
• Secukinumab 100%
• Biological Product 30%
• Interleukin 17 10%
• Survival Rate 10%